PAN-TB regimens to address growing TB drug resistance
By Dr. Charles Wells, head of therapeutics development at Gates Medical Research Institute As nearly…
By Dr. Charles Wells, head of therapeutics development at Gates Medical Research Institute As nearly…
By Thierry Escudier, consultant and strategic leader at The Pistoia Alliance The move towards patient…
By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way…
By Sander Slootweg, managing partner, Forbion More than 300 million people around the globe are…
By Michael Arciero, vice president of intellectual property and corporate development, ERS Genomics Michael Arciero,…
By Gary Shorter, head of artificial intelligence at IQVIA Clinical trials are currently in an…
By Markus Gershater, co-founder and chief scientific officer, Synthace The buzz surrounding generative AI has…
By Joe Oakley, MD, medical director of biomarker development, Paige Just as much of medicine…
By Victoria Zazulina, M.D., head of development unit, oncology, for the healthcare business of Merck…
By Michael Pisano, executive vice president, proteomics, Discovery Life Sciences In oncology, characterizing genetic markers…
By Ian B. Walters, chief executive officer and chairman, Portage Biotech In recent years, PD-1/PD-L1…
By Oxford BioDynamics Cancer care is in urgent need of effective tests to determine the…